regulation: atmp vs minimally manipulated immune cells
Published 4 years ago • 98 plays • Length 4:12Download video MP4
Download video MP3
Similar videos
-
2:49
the role of the immune system in the pathophysiology of mds
-
2:25
master final analysis: quadruplet induction therapy, asct & mrd-adapted treatment cessation in ndmm
-
2:05
alnuctamab: improved route of administration and optimized dose level & dosing schedule
-
2:21
the potential applications for immunotherapy in mpns
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
5:33
syaraf terjepit penyebab migrain langsung sembuh🔥‼️ #masterjoetherapy #bonesetting #yt
-
7:27
menin inhibitors in aml: mechanism of action, the current key data, and predicting efficacy
-
2:07
immune checkpoint inhibitors, the next generation cancer therapy - creative biolabs
-
1:38
a phase i study of wvt078, a bcma×cd3 bsab, with a gamma-secretase inhibitor (whg626) in r/r mm
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
1:14
highlights in quality management from ebmt
-
1:56
investigating linvoseltamab monotherapy in smm: the linker-smm1 trial
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
3:17
ziftomenib: mechanism of action and promising results in patients with kmt2ar or npm1m aml
-
2:43
the management of advanced phase mpns
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
0:56
the evolving treatment landscape in pv
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
1:09
the main aims of the t2evolve consortium